Jade Biosciences, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum
Jade Biosciences, Inc. (JBIO) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum of 89.80% for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-27.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum · last filed 2025-03-27
- Jade Biosciences, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, maximum for the quarter ending 2023-09-30 was 91.50%, a 23.98% increase year-over-year.
- Jade Biosciences, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, maximum for the quarter ending 2023-06-30 was 76.30%, a 0.26% decline year-over-year.
- Jade Biosciences, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, maximum for the quarter ending 2023-03-31 was 76.71%, a 1.36% increase year-over-year.
- Jade Biosciences, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, maximum for the quarter ending 2022-09-30 was 73.80%, a 6.19% increase year-over-year.
- Jade Biosciences, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, maximum for fiscal 2024 was 89.80%, a 1.86% decline from fiscal 2023.
- Jade Biosciences, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, maximum for fiscal 2023 was 91.50%, a 19.61% increase from fiscal 2022.
- Jade Biosciences, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, maximum for fiscal 2022 was 76.50%, a 9.60% increase from fiscal 2021.
- Jade Biosciences, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, maximum for fiscal 2021 was 69.80%, a 12.09% decline from fiscal 2020.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum 12 month |
|---|---|---|---|---|
| 2024-12-31 | 89.80% 10-K · filed 2025-03-27 | |||
| 2023-12-31 | 91.50% 10-K · filed 2025-03-27 | |||
| 2023-09-30 | 91.50% 10-Q · filed 2023-11-13 | 91.50% 10-Q · filed 2023-11-13 | ||
| 2023-06-30 | 76.30% 10-Q · filed 2023-08-14 | 76.70% 10-Q · filed 2023-08-14 | ||
| 2023-03-31 | 76.71% 10-Q · filed 2023-05-15 | |||
| 2022-12-31 | 76.50% 10-K · filed 2024-03-25 | |||
| 2022-09-30 | 73.80% 10-Q · filed 2023-11-13 | 76.50% 10-Q · filed 2023-11-13 | ||
| 2022-06-30 | 76.50% 10-Q · filed 2023-08-14 | 76.50% 10-Q · filed 2023-08-14 | ||
| 2022-03-31 | 75.68% 10-Q · filed 2023-05-15 | |||
| 2021-12-31 | 69.80% 10-K · filed 2023-03-29 | |||
| 2021-09-30 | 69.50% 10-Q · filed 2022-11-14 | 69.60% 10-Q · filed 2022-11-14 | ||
| 2021-06-30 | 69.60% 10-Q · filed 2022-08-15 | 69.60% 10-Q · filed 2022-08-15 | ||
| 2020-12-31 | 79.40% 10-K · filed 2022-03-30 | |||
| 2020-09-30 | 72.80% 10-Q · filed 2021-11-15 | 79.40% 10-Q · filed 2021-11-15 | ||
| 2020-06-30 | 79.40% 10-Q · filed 2021-08-16 | 79.40% 10-Q · filed 2021-08-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |